RxDoctor Payments Data

Sharon Roble, MD

Cardiovascular Disease · Mansfield, OHNPI 1548474471

Payments from drug & device makers

$1,484in general payments, 2019–2025

Across 23 payments — averaging $64.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$283
  • Astellas Pharma US Inc$236
  • Heartflow, Inc.$224
  • Amgen$184
  • AstraZeneca$139
  • Novo Nordisk$113
  • plus $305 from 6 others

What the payments were for

  • Food & beverage$1,18080%
  • Education$30420%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,484 in reported general payments places this provider in the 45th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$87,821
Medicare patients
959
Services billed
1,640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban153$201,290
XareltoRivaroxaban29$36,845
Metoprolol Succinate252$3,940
Ranolazine ErRanolazine18$2,685
Atorvastatin Calcium217$2,194
Potassium Chloride75$1,230
Losartan Potassium113$1,125
ClopidogrelClopidogrel Bisulfate91$1,097
Flecainide Acetate27$1,017
Prasugrel Hcl24$907
Carvedilol108$796
Amiodarone Hcl14$694
Metoprolol Tartrate96$633
Lisinopril106$631
Isosorbide Mononitrate ErIsosorbide Mononitrate55$625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$201,290153 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Mansfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →